|
.
|
|
0 (hodnocen0 x )
|
|
EB
|
|
ONLINE
|
|
|
|
|
|
Cham : Springer International Publishing AG, 2015
|
|
1 online resource (82 pages)
|
Externí odkaz
|
Plný text PDF
|
|
* Návod pro vzdálený přístup
|
|
|
|
|
|
ISBN 9783319254609 (electronic bk.)
|
|
ISBN 9783319254586
|
|
Print version: Shantsila, Eduard Non-Vitamin K Antagonist Oral Anticoagulants Cham : Springer International Publishing AG,c2015 ISBN 9783319254586
|
|
|
|
Intro -- Contents -- Chapter 1: Introduction -- 1.1 Overview of the Coagulation Cascade -- 1.2 Current Approaches to Anticoagulation -- 1.3 The Ideal Anticoagulant -- References -- Chapter 2: Direct Thrombin Inhibitors -- 2.1 Historical Excursus: Ximelagatran -- 2.2 Dabigatran Etexilate -- 2.2.1 Venous Thromboembolism Prevention in Major Orthopedic Surgery -- 2.2.2 Venous Thromboembolism Treatment -- 2.2.3 Stroke Prevention in Atrial Fibrillation -- 2.2.4 Other Directions -- References -- Chapter 3: Factor Xa Inhibitors -- 3.1 Rivaroxaban -- 3.1.1 Venous Thromboembolism Prevention following Joint Surgery -- 3.1.2 Treatment of Venous Thromboembolism -- 3.1.3 Stroke Prevention in Atrial Fibrillation -- 3.1.4 Acute Coronary Syndromes -- 3.2 Apixaban -- 3.2.1 Venous Thromboembolism Prevention in Major Orthopedic Surgery -- 3.2.2 Stroke Prevention in Atrial Fibrillation -- 3.2.3 Thromboprophylaxis in Other Clinical Settings -- 3.2.4 Treatment of Venous Thrombosis -- 3.2.5 Acute Coronary Syndrome -- 3.3 Edoxaban -- 3.3.1 Venous Thromboembolism Prevention in Major Orthopedic Surgery -- 3.3.2 Stroke Prevention in Atrial Fibrillation -- 3.3.3 Treatment of Venous Thromboembolism -- 3.4 Emerging Factor Xa Inhibitors -- 3.4.1 Betrixaban -- 3.4.2 TTP889 -- References -- Chapter 4: Conclusions -- 4.1 Future Directions -- References.
|
|
|
|
001895166
|
|
express
|
|
(Au-PeEL)EBL6422746
|
|
(MiAaPQ)EBC6422746
|
|
(OCoLC)1066198411
|